🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  2. LIBTAYO 350 mg concentrate for solution for infusion., Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  3. LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., REGN10597

    Lacuna Pharma Pty Ltd

    Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  4. LIBTAYO 350 mg concentrate for solution for infusion., Vidutolimod, Vidutolimod

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  5. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  6. LISINOPRIL , XXB750, AZILSARTAN MEDOXOMIL , CANDESARTAN , BENAZEPRIL , TRANDOLAPRIL , FOSINOPRIL , PERINDOPRIL , MOEXIPRIL , QUINAPRIL , CAPTOPRIL , EPROSARTAN , RAMIPRIL , IRBESARTAN , VALSARTAN AND SACUBITRIL , ZOFENOPRIL , CILAZAPRIL , DELAPRIL , OLMESARTAN MEDOXOMIL , IMIDAPRIL , 0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection, ENALAPRIL , TELMISARTAN , VALSARTAN , LOSARTAN

    Novartis Pharmaceuticals

    Heart Failure

    phase 2 small molecule active

    1 trial

  7. LNA043

    Novartis Pharmaceuticals

    Osteoarthritis

    phase 2 small molecule active

    1 trial

  8. LOU064, -, -, Placebo to LOU064 Film-coated tablet

    Novartis Pharmaceuticals

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  9. LP-08 80mg

    LIPELLA PHARMACEUTICALS INC.

    Interstitial Cystitis

    phase 2 small molecule completed

    1 trial

  10. LP-10

    LIPELLA PHARMACEUTICALS INC.

    Hemorrhagic Cystitis

    phase 2 small molecule completed

    1 trial

  11. LP-10 (Liposomal Tacrolimus)

    LIPELLA PHARMACEUTICALS INC.

    Oral Lichen Planus

    phase 2 small molecule active

    1 trial

  12. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  13. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis (PSC)

    phase 2 small molecule completed

    1 trial

  14. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cirrhosis

    phase 2 small molecule terminated

    1 trial

  15. LUM001

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    2 trials

  16. LUM001

    Mirum Pharmaceuticals International B.V.

    PBC

    phase 2 small molecule completed

    1 trial

  17. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    3 trials

  18. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 2 small molecule completed

    1 trial

  19. LUMYKRAS 120 mg film-coated tablets, LUMYKRAS 240 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  20. LX1031 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  21. LX3305 low dose

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  22. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  23. LX6171 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Age-Related Memory Disorders

    phase 2 small molecule completed

    1 trial

  24. LX7101 (0.125%)

    LEXICON PHARMACEUTICALS, INC.

    Primary Open-angle Glaucoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources